Medical Technology and Medicines
Current Projects
Various assumptions lie behind the Government's thinking on changing the way we price medicines in the UK. Changing the existing 50 year-old refined system is a risk, and building on our 'Implementing value-based pricing' report produced with the London School of Economics in early 2010 we are looking further into the assumptions that have been made, the impact of VBP in other countries, the consequences of weakening NICE, the morality of the QALY and how to balance industrial and health policy.